Editas Medicine, Inc.

Editas Medicine, Inc.

1.72
EUR
-0.02
(-1.15%)
-0.54EPS
354.95MMarket Cap
Feb 25Next Earn

Total Valuation

EUR

As of September 30, 2026, Editas Medicine, Inc. carries a market capitalization of 354.95M, placing it among publicly traded companies globally. Its enterprise value stands at 199.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap354.95M
Enterprise Value199.44M

Important Dates

Editas Medicine, Inc.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of September 30, 2026, Editas Medicine, Inc. has 153.66M shares outstanding.

Shares Outstanding153.66M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 6.15, and the price-to-book ratio stands at 4.76.

PS Ratio6.15
PB Ratio4.76
P/TBV Ratio4.76
P/FCF Ratio-2.77
P/OCF Ratio-2.78

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 4.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 199.44M versus a market cap of 354.95M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales4.54

Financial Position

As of September 30, 2026, Editas Medicine, Inc. maintains a current ratio of 2.82, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 16.49, indicating elevated leverage, while an interest coverage ratio of -26.72 demonstrates limited ability to service its debt obligations.

Current Ratio2.82
Quick Ratio2.77
Debt / Equity16.49
Debt / EBITDA-0.19
Interest Coverage-26.72

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, Editas Medicine, Inc. posted a negative return on equity (ROE) of -147.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -34.30, reflecting losses generated across the asset base. The company generates approximately 505,314.51 in revenue per employee across its workforce of 87.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-147.44
Return on Assets (ROA)-34.30
Revenue Per Employee505,314.51
Employee Count87.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Editas Medicine, Inc.'s stock has declined approximately 22.84% over the past 52 weeks. The 50-day moving average sits at 2.29, while the 200-day moving average is 2.36.

52-Week Price Change-22.84%
50-Day Moving Average2.29
200-Day Moving Average2.36

Income Statement

EUR

Over the twelve months ended September 30, 2026, Editas Medicine, Inc. generated 43.96M in revenue and converted that into -63.72M in net income, yielding earnings per share of -0.54. EBITDA reached -64.85M, while operating income came in at -73.40M.

Revenue43.96M
Operating Income-73.40M
Pretax Income-63.72M
Net Income-63.72M
EBITDA-64.85M
EBIT-66.70M
Earnings Per Share (EPS)-0.54

Balance Sheet

EUR

As of September 30, 2026, Editas Medicine, Inc. holds 167.81M in cash and equivalents against 12.30M in total debt, resulting in a net debt position of -82.20M. Total book value stands at 74.57M, with working capital of 115.04M providing operational flexibility.

Cash & Cash Equivalents167.81M
Total Debt12.30M
Net Debt-82.20M
Equity (Book Value)74.57M
Book Value Per Share0.49
Working Capital115.04M

Cash Flow

EUR

Editas Medicine, Inc. produced -97.23M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -227,633.40 in capital expenditures, free cash flow totaled -97.46M - equivalent to -0.83 per share.

Operating Cash Flow-97.23M
Capital Expenditures-227,633.40
Free Cash Flow-97.46M
FCF Per Share-0.83

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -166.97 and net profit margin of -144.95 provide insight into operational efficiency.

Operating Margin-166.97
Pretax Margin-144.95
Profit Margin-144.95
EBITDA Margin-147.52

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -36.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -33.41, meaning Editas Medicine, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-33.41
FCF Yield-36.06

Scores

As of September 30, 2026, Editas Medicine, Inc. has an Altman Z-Score of -9.34, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-9.34